How to buy Immutep (IMM) shares
Learn how to easily invest in Immutep shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Immutep is a biotechnology business based in Australia. Immutep shares (IMM) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Immutep has a trailing 12-month revenue of around $3.9 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Immutep
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Immutep . Find the share by name or ticker symbol: IMM. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Immutep reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Immutep . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Immutep stock price (ASX:IMM)Use our graph to track the performance of IMM stocks over time.
Immutep shares at a glance
|52-week range||$0.295 - $0.725|
|50-day moving average||$0.5087|
|200-day moving average||$0.5245|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.05|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Immutep stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Immutep price performance over time
|1 week (2022-01-13)||-4.26%|
|1 month (2021-12-21)||-6.25%|
|3 months (2021-10-21)||-22.41%|
|6 months (2021-07-21)||-10.00%|
|1 year (2021-01-21)||4.65%|
|2 years (2020-01-20)||50.00%|
|3 years (2019-01-18)||-85.84%|
|5 years (2017-01-20)||-87.42%|
|Revenue TTM||$3.9 million|
|Gross profit TTM||$-13,373,974|
|Return on assets TTM||-19.1%|
|Return on equity TTM||-56.12%|
|Market capitalisation||$340.4 million|
TTM: trailing 12 months
Immutep share dividends
We're not expecting Immutep to pay a dividend over the next 12 months.
Have Immutep 's shares ever split?
Immutep 's shares were split on a 1:10 basis on 4 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immutep shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Immutep shares which in turn could have impacted Immutep 's share price.
Immutep share price volatility
Over the last 12 months, Immutep 's shares have ranged in value from as little as $0.295 up to $0.725. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Immutep 's is 1.536. This would suggest that Immutep 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Stocks similar to Immutep
Immutep in the news
Frequently asked questions
More guides on Finder
RAT scams: How to avoid getting conned with rapid antigen tests
Don't fall for the scam artists when you're trying to protect your health - here's what to check.
How to do a COVID-19 test at home for international travel
Here's where you can book COVID-19 at-home tests approved for travel and how they work.
Where to shop every product in Kiernan Shipka’s beauty routine
We've rounded up everything you need to nail the 'date-worthy' makeup look, including some affordable dupes.
American Express Corporate Gold Card
Designed for big companies, this Amex charge card offers a mix of management tools and perks – including a 100,000 bonus Membership Rewards offer.
Rapid antigen tests: When will RAT stock be available? [UPDATED]
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
Beauty Product of the Week: Milk Makeup Hydro Grip Primer
We tried the viral Milk Makeup Hydro Grip Primer and spoiler alert, it's the bee's knees.
Where to watch Hotel Transylvania 4 online for free in Australia
Drac and the Pack are back, like you’ve never seen them before.
Dyson V12 Detect Slim review: Baby love, my baby love
A delightful compact vacuum with an unjustifiable price.
Stan Event: Streaming platform joins pay-per-view ranks
A new player enters the Australian sports broadcast market.
Amazon Echo Buds (2nd Gen) review: Fine if you’re already trapped by Bezos
The Amazon Echo Buds 2 are a solid addition to your earholes if you’re already integrated in the Alexa ecosystem. But if you’re not, its hard to find anything here that really stands out.
Ask an Expert